News

AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO
AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of ...
Applied Clinical Trials Online1h
AstraZeneca and Daiichi Sankyo Share Positive Data From Phase III DESTINY-Breast09 Trial of Enhertu Plus Pertuzumab
In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...
Fierce Biotech10h
ASCO: AstraZeneca's oral SERD tied to 56% PFS benefit in phase 3 breast cancer trial
AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% ...
BioPharma Dive7h
Enhertu potential broadens as new data point to frontline breast cancer role
Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...
STAT1d
AstraZeneca’s CEO balances cancer-fighting opportunities with political uncertainty
AstraZeneca CEO Pascal Soriot views the company's stock price — up just 10% year-to-date — as a marker of how he is doing. He ...
CNBCTV1817h
AstraZeneca Pharma India shares rise 8% after revenue, margin jump in Q4
Shares of AstraZeneca Pharma India Ltd. are trading over 8% higher on Monday, June 2, after the company reported its ...
Explore more
AstraZeneca falls Monday, underperforms market
AstraZeneca PLC closed 21.02% short of its 52-week high of £133.88, which the company reached on September 3rd.
AstraZeneca agrees to $51 million settlement in Seroquel antitrust class action
Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of ...